01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology

01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology

Data sources

SEC FORM 419m ago

HOUSE PTR19m ago

SEC 13F19m ago

ROBINHOOD CHAIN19m ago

Public company

NVAXNOVAVAX INC

CIK 0001000694

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections3with evidence

NVAX · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
← Lobbied forevidence
BALLARD PARTNERSLDA Q1 2026 first quarter · MED · Aug 26, 2026
← Lobbied forevidence
BROWNSTEIN HYATT FARBER SCHRECK, LLPLDA Q2 2026 second quarter · Health issues · Aug 26, 2026

Lobbying

$270K reported · de-duplicated

2026 Q2 $130K in-house2026 Q1 $140K in-house

In-house report$130K2026 Q2 · posted Aug 26, 2026 · Health issues
In-house report$140K2026 Q1 · posted Aug 26, 2026 · Health issues
BALLARD PARTNERS$50K2026 Q2 · posted Aug 26, 2026 · MED
BALLARD PARTNERS$50K2026 Q1 · posted Aug 26, 2026 · MED
BROWNSTEIN HYATT FARBER SCHRECK, LLP$50K2026 Q1 · posted Aug 26, 2026 · Health issues
BROWNSTEIN HYATT FARBER SCHRECK, LLP$50K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.